慢性肾脏病中抗体介导纯红细胞再生障碍性贫血的研究进展  

Research progress on antibody-mediated pure red cell aplasia in chronic kidney disease

作　　者：游晓娥 马华林[1,2] 王圳 张欣洲 郭宝春[1,2] You Xiaoe;Ma Hualin;Wang Zhen;Zhang Xinzhou;Guo Baochun(The Second Clinical Medical College,Jinan University,Shenzhen 518020,China)

机构地区：[1]暨南大学第二临床医学院,深圳518020 [2]深圳市人民医院(暨南大学第二临床医学院,南方科技大学第一附属医院)肾内科,深圳518020

出　　处：《新医学》2023年第6期388-392,共5页Journal of New Medicine

基　　金：广东省高水平临床重点专科基金(深圳市配套建设经费)(SZGSP001);深圳市科技创新委员会可持续发展专项(KCXFZ20201221173612034)。

摘　　要：红细胞生成素及其类似物是治疗慢性肾脏病(CKD)、恶性肿瘤及化学治疗、自身免疫性疾病和营养不良等引起的贫血最有效的药物。但部分患者尤其是CKD患者在使用促红细胞生成素后产生中和抗体,从而导致纯红细胞再生障碍性贫血(PRCA)的发生,严重影响患者的病情与预后。全面了解抗体介导的PRCA将有助于早期发现疾病,给予适当的检测方法,从而制定合理的治疗措施,有利于改善CKD患者预后。该文对CKD中抗体介导的PRCA研究进展进行了系统综述。Erythropoietin and its analogues are the most effective drugs for the treatment of anemia caused by chronic kidney disease(CKD),malignant tumors and chemotherapy,autoimmune disorders,and malnutrition,etc.However,partial patients,especially CKD patients,can generate neutralizing antibody after use of erythropoiesis-stimulating agents,thereby leading to pure red cell aplasia(PRCA)and severely affecting disease condition and clinical prognosis.Full understanding of antibody-induced PRCA contributes to delivering early diagnosis,appropriate examinations and effective treatment,and enhancing clinical prognosis of CKD patients.In this article,research progress upon antibody-induced PRCA in CKD patients was systematically reviewed.

关 键 词：红细胞生成素 纯红细胞再生障碍性贫血 慢性肾脏病 罗沙司他 

分 类 号：R692[医药卫生—泌尿科学] R556.5[医药卫生—外科学]